FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely cardiology, and can be used to predict cardiovascular risk by determining the level of estrogens. The degree of risk is determined based on the indicators of the endocrine status of the patient. After determining the level of blood estradiol by electrochemiluminescence immunoassay, a correlation is carried out with the degree of cardiovascular risk of a patient suffering from chronic cardiovascular diseases according to the following criteria: for men, low cardiovascular risk corresponds to an estradiol level of more than 55.55 pg/ml, moderate cardiovascular risk corresponds to an estradiol level of 32.17-55.54 pg/ml, high cardiovascular risk corresponds to an estradiol level of 10.44-32.16 pg/ml, very high cardiovascular risk corresponds to an estradiol level of less than 10.43 pg/ml; for postmenopausal women, low cardiovascular risk corresponds to an estradiol level of more than 76.32 pg/ml, moderate cardiovascular risk corresponds to an estradiol level of 43.29-76.31 pg/ml, high cardiovascular risk corresponds to an estradiol level of 15.95-43.28 pg/ml, very high cardiovascular risk corresponds to an estradiol level of less than 15.94 pg/ml.
EFFECT: method provides an opportunity to increase the effectiveness and prognostic value of a comprehensive determination of cardiovascular risk by determining the level of blood estradiol by electrochemiluminescence immunoassay (ECLIA) and based on the obtained indicators of correlation with the degree of cardiovascular risk of a patient suffering from chronic cardiovascular diseases.
1 cl, tbl, 3 ex
